Brought to you by 
Ra Pharmaceuticals completes first tranche of potential $27.6mm Series A round
31 May 2012
Executive Summary
Two-year old Ra Pharmaceuticals Inc. (drug discovery) has raised $10.33mm through five backers including New Enterprise Associates (lead), Amgen Ventures, Morganthaler Ventures, and Novartis Venture Funds. This completes the first tranche of a potential $27.6mm Series A round.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
-
Drug Discovery Tools
- Molecular Diversity
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Ra Pharmaceuticals completes first tranche of potential $27.6mm Series A round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice